Related Experiment Video
Updated: Jan 22, 2026
Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
Published on: September 20, 2018
Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification
Arie Levine1, Anne Griffiths, James Markowitz
1Wolfson Medical Center, Tel Aviv University, Israel.
Insights
The Paris Classification offers updated criteria for pediatric inflammatory bowel disease (IBD), improving upon the Montreal Classification by capturing dynamic disease features like growth failure and precise location. This standardized approach aids IBD research and genotype-phenotype correlations.
Area of Science:
- Pediatric Gastroenterology
- Inflammatory Bowel Disease (IBD) Research
- Clinical Phenotyping
Background:
- Inflammatory bowel disease (IBD) encompasses Crohn's disease and ulcerative colitis, complex conditions with shared and distinct genetic underpinnings.
- Accurate phenotyping is crucial for genotype-phenotype correlations in IBD research.
- The existing Montreal Classification has limitations in classifying pediatric IBD phenotypes, failing to capture dynamic disease characteristics such as changes in location, behavior, and growth failure over time.
Purpose of the Study:
- To develop evidence-based consensus recommendations for a pediatric modification of the Montreal Classification criteria for IBD.
- To establish uniform standards for defining IBD phenotypes in pediatric research.
- To facilitate research in pediatric inflammatory bowel disease.
Main Methods:
- An international group of pediatric IBD experts convened in Paris, France.
- The experts focused on creating a modified classification system based on the Montreal framework.
- Consensus recommendations were developed through an evidence-based approach.
Main Results:
- The revised classification, termed the Paris Classification, includes age at diagnosis categories (A1a, A1b, A2, A3).
- It incorporates detailed distinctions for disease location (L4a, L4b) and behavior (B2B3 for combined stenosing and penetrating disease).
- New indicators for growth failure (G(1) vs. G(0)), extent of ulcerative colitis (E4), and ever severe disease (S1) were added.
Conclusions:
- The Paris Classification provides enhanced criteria for pediatric IBD, addressing the limitations of the Montreal Classification.
- These modifications capture dynamic disease features crucial for pediatric patients, including growth failure.
- The Paris Classification maintains compatibility with the Montreal framework, ensuring its utility for adult-onset disease and adult gastroenterologists.
Background:
Crohn's disease and ulcerative colitis are complex disorders with some shared and many unique predisposing genes. Accurate phenotype classification is essential in determining the utility of genotype-phenotype correlation. The Montreal Classification of IBD has several weaknesses with respect to classification of children. The dynamic features of pediatric disease phenotype (change in disease location and behavior over time, growth failure) are not sufficiently captured by the current Montreal Classification.
Methods:
Focusing on facilitating research in pediatric inflammatory bowel disease (IBD), and creating uniform standards for defining IBD phenotypes, an international group of pediatric IBD experts met in Paris, France to develop evidence-based consensus recommendations for a pediatric modification of the Montreal criteria.
Results:
Important modifications developed include classifying age at diagnosis as A1a (0 to <10 years), A1b (10 to <17 years), A2 (17 to 40 years), and A3 (>40 years), distinguishing disease above the distal ileum as L4a (proximal to ligament of Treitz) and L4b (ligament of Treitz to above distal ileum), allowing both stenosing and penetrating disease to be classified in the same patient (B2B3), denoting the presence of growth failure in the patient at any time as G(1) versus G(0) (never growth failure), adding E4 to denote extent of ulcerative colitis that is proximal to the hepatic flexure, and denoting ever severe ulcerative colitis during disease course by S1.
Conclusions:
These modifications are termed the Paris Classification. By adhering to the Montreal framework, we have not jeopardized or altered the ability to use this classification for adult onset disease or by adult gastroenterologists.
Related Concept Videos
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:30Classification of Neurotransmitters
01:30Classification of Leukocytes
Neutrophils are the most abundant type of granular leukocytes, comprising 50-70% of all leukocytes. They feature small, evenly distributed granules and a...